Status:
COMPLETED
A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This study has 2 parts. Researchers want to learn what happens to MK-1084 in a healthy person's body over time in both parts. The goals of the study are: * In Part 1, to compare what happens to MK-10...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- \- Has a body mass index ≥18.0 and ≤32.0 kg/m\^2
Exclusion
- The main exclusion criteria include but are not limited to the following:
- Has a history or presence of a clinically significant medical or psychiatric condition or disease
- Has a history of cancer (malignancy)
- Has positive results for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus
Key Trial Info
Start Date :
May 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2025
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06942741
Start Date
May 13 2025
End Date
August 4 2025
Last Update
October 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion ( Site 0001)
Tempe, Arizona, United States, 85283